Public Disclosure of the Filing of New Drug and Therapeutic Biologics Applications With the US Food and Drug Administration.

Chahal, Harinder Singh; Szeto, David; Chaudhry, Anam H; Sigelman, Daniel W; Kim, Stella; Lurie, Peter G

Chahal, Harinder Singh; Szeto, David; Chaudhry, Anam H; Sigelman, Daniel W; Kim, Stella; Lurie, Peter G.

Afiliación

Chahal HS; Office of Public Health Strategy and Analysis, Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland.
Szeto D; Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick.
Chaudhry AH; Office of Public Health Strategy and Analysis, Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland.
Sigelman DW; Office of Public Health Strategy and Analysis, Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland.
Kim S; Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Lurie PG; Center for Science in the Public Interest, Washington, DC.

JAMA Intern Med ; 179(8): 1144-1146, 2019 Aug 01.

Article en En | MEDLINE | ID: mdl-31157824

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JAMA Intern Med Año: 2019 Tipo del documento: Article